Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 8/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030873 | 0.85 | KMT2A (0.54) | MAPTKMT2AMEN1APLNRELANE | |
| SCHEMBL3030393 | 0.75 | CA12 (0.44) | MAPTKMT2AMEN1POLBALOX12 | |
| SCHEMBL10328549 | 0.73 | CYP1A2 (0.44) | MAPTKMT2AMEN1POLBAPLNR | |
| SCHEMBL13177337 | 0.71 | KMT2A (0.52) | MAPTKMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL3026330 | 0.71 | KMT2A (0.43) | MAPTKMT2AELANESMN1; SMN2MAPK1 | |
| SCHEMBL2831997 | 0.70 | KMT2A (0.54) | MAPTKMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL2833903 | 0.70 | CYP1A2 (0.56) | MAPTKMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL2838559 | 0.69 | SMN1; SMN2 (0.46) | MAPTKMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL23235066 | 0.69 | RAB9A (0.49) | MAPTKMT2AMEN1SMN1; SMN2NPC1 | |
| SCHEMBL17196170 | 0.69 | SMN1; SMN2 (0.35) | MAPTKMT2AMEN1ELANESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183398-B2 | 5-hydroxy-2-methyl-4H-pyran-4-one esters as novel tyrosinase inhibitors | EASTMAN CHEMICAL COMPANY (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2245024-A1 | 5-HYDROXY-2-METHYL-4H-PYRAN-4-ONE-ESTERS AS NOVEL TYROSINASE INHIBITORS | Eastman Chemical Company (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100216873-A1 | 5-Hydroxy-2-Methyl-4H-Pyran-4-One Esters as Novel Tyrosinase Inhibitors | EASTMAN CHEMICAL COMPANY (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2009108272-A1 | 5-HYDROXY-2-METHYL-4H-PYRAN-4-ONE-ESTERS AS NOVEL TYROSINASE INHIBITORS | EASTMAN CHEMICAL COMPANY (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215887-A1 | 5-HYDROXY-2-METHYL-4H-PYRAN-4-ONE ESTERS AS NOVEL TYROSINASE INHIBITORS | EASTMAN CHEMICAL COMPANY (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215887-A1 | 5-HYDROXY-2-METHYL-4H-PYRAN-4-ONE ESTERS AS NOVEL TYROSINASE INHIBITORS | TYR, CYP51A1, TH | MAPT 2600/4885KMT2A 667/4885MEN1 4068/4885 |
| US-20100216873-A1 | 5-Hydroxy-2-Methyl-4H-Pyran-4-One Esters as Novel Tyrosinase Inhibitors | TYR, CYP51A1, TH | MAPT 2600/4885KMT2A 667/4885MEN1 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.